Johnson & Johnson

Explore the latest insights on Johnson & Johnson and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Johnson & Johnson’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.Explore the latest insights on Johnson & Johnson and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Johnson & Johnson's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Cutia Therapeutics Secures Macao Marketing Approval for CU‑40102 Topical Finasteride Spray – Completing Greater China Rollout in Androgenetic Alopecia
CompanyDrug

Cutia Therapeutics Secures Macao Marketing Approval for CU‑40102 Topical Finasteride Spray – Completing Greater China Rollout in Androgenetic Alopecia

Cutia Therapeutics (HKG: 2487) announced that CU‑40102, its topical finasteride spray, has been approved for marketing in Macao, China, for the treatment of androgenetic alopecia – extending the product's Greater…

Qilu Pharmaceutical Drops RMB 400 Million Equity Stake in TYK Medicines – But TY‑9591 Licensing and China Commercialization Deal Stays Alive

Qilu Pharmaceutical Drops RMB 400 Million Equity Stake in TYK Medicines – But TY‑9591 Licensing and China Commercialization Deal Stays Alive

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Johnson & Johnson MedTech's Varipulse Platform Receives FDA Approval for Atrial Fibrillation Treatment
CompanyMedical Device

Johnson & Johnson MedTech’s Varipulse Platform Receives FDA Approval for Atrial Fibrillation Treatment

Huadong Medicine Co., Ltd Receives NMPA Approval for Stelara Biosimilar SaiLeXin
CompanyDrug

Huadong Medicine Co., Ltd Receives NMPA Approval for Stelara Biosimilar SaiLeXin

J&J MedTech Completes Pilot Enrollment for OMNY-AF Study on Atrial Fibrillation Treatment
CompanyMedical Device

J&J MedTech Completes Pilot Enrollment for OMNY-AF Study on Atrial Fibrillation Treatment

Johnson & Johnson's Akeega Approved in China as First Dual Action Tablet for mCRPC
CompanyDrug

Johnson & Johnson’s Akeega Approved in China as First Dual Action Tablet for mCRPC

Johnson & Johnson's Nipocalimab Shows Promise in Treating Adolescent Myasthenia Gravis in Phase II/III Trial
CompanyDrug

Johnson & Johnson’s Nipocalimab Shows Promise in Treating Adolescent Myasthenia Gravis in Phase II/III Trial

J&J Reports Q3 2024 Revenue Growth, Raises Full-Year Guidance on Strong Pipeline Progress
Company

J&J Reports Q3 2024 Revenue Growth, Raises Full-Year Guidance on Strong Pipeline Progress

Intas Pharmaceuticals Receives FDA Approval for Biosimilar Stelara, Expanding Treatment Options for Autoimmune Diseases
CompanyDrug

Intas Pharmaceuticals Receives FDA Approval for Biosimilar Stelara, Expanding Treatment Options for Autoimmune Diseases

Johnson & Johnson’s KLK2-CD3 Bispecific Antibody JNJ-78278343 Advances in Prostate Cancer Clinical Trials
Drug

Johnson & Johnson’s KLK2-CD3 Bispecific Antibody JNJ-78278343 Advances in Prostate Cancer Clinical Trials

Show More